Moderna files for Emergency Use Authorisation for its COVID-19 vaccine in adolescents in US

In May, the company announced that its Phase II/III TeenCOVE trial in adolescents hit the primary immunogenicity endpoint. The efficacy in almost 2,500 adolescents who received the vaccine was 100%, meaning no participants contracted COVID-19.

SPS commentary:

The European Medicines Agency is currently evaluating the use of COVID-19 Vaccine Moderna in young people aged 12 to 17. Outcome is expected in July.

Source:

Biospace Inc.